A Study to Assess the Clinical Efficacy of IONIS-PKK-LRx in Participants With Hereditary Angioedema
Status:
Completed
Trial end date:
2021-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the clinical efficacy, safety, and tolerability of
IONIS-PKK-LRx in participants with hereditary angioedema (HAE) type 1 (HAE-1), HAE type 2
(HAE-2), or HAE with normal C1-inhibitor (C1-INH) and to evaluate the effect of IONIS-PKK-LRx
on plasma prekallikrein (PKK) and other relevant biomarkers.